Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardioPolymers Inc.

Division of LoneStar Heart Inc.
www.symphonymed.com

Latest From CardioPolymers Inc.

Renal Denervation Sparks Device Market Gold Rush

With the recent success of Ardian’s Symplicity Renal Denervation System, drug-resistant hypertension has emerged as something of a device market “gold rush.” Some observers estimate there are now as many as 40 companies developing various device-based therapies for resistant hypertension, including most of the big names in the cardiovascular device arena – Medtronic, St. Jude Medical, Boston Scientific, Johnson & Johnson, and Covidien PLC – along with a number of start-ups, all of which are racing to stake a claim in this highly promising market. Only time will tell which companies will be successful – even Medtronic, the first player, has yet to complete its sham-controlled US trial. But the technology’s early promise, along with the sheer size of the opportunity and the acute unmet need, clearly have peaked the interest of investors, manufacturers, and physicians alike, all of whom are chasing after what one participant has called “the next biggest thing in cardiology.”

Medical Device Innovation

Start-Up News

Noteworthy news from medtech start-ups. This month we profile CardioPolymers Inc., which is developing a highly purified form of seaweed that, when implanted into the heart, has the potential to stop or even reverse the progression of congestive heart failure. We also profile Aura Medsystems, which is developing photodynamic soft-tissue repair technology.
Medical Device

Dealmaking in 2009: A Look Back and A Glance Ahead

This article was excerpted from "Top Device Stories of 2009: A Year of Economic Revival and Regulatory Risk," IN VIVO, January 2010.
Medical Device

The A-List: 2009's Trend-Shaping Series A Financings

New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. In biopharmaceuticals, corporate venture got in at the ground floor while device start-ups continued to see stronger support from smaller, regional investors than traditional VCs.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Symphony Medical Inc.
  • RHYTHM THERAPEUTICS CORP
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • LoneStar Heart Inc.
  • Lonestar Heart Inc.
  • Senior Management
  • Andres C Ramos, CEO
    Tony Chelew, CFO
  • Contact Info
  • CardioPolymers Inc.
    Phone: (949) 215-3613
    26051 Merit Circle
    Ste. 102
    Laguna Hills, CA 92653
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register